Karyopharm Therapeutics Files 8-K
Ticker: KPTI · Form: 8-K · Filed: Oct 31, 2024 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Oct 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-disclosure, sec-filing
Related Tickers: KPTI
TL;DR
Karyopharm filed an 8-K on 10/31/24 - check for updates.
AI Summary
Karyopharm Therapeutics Inc. filed an 8-K on October 31, 2024, to report on various corporate events. The filing includes information related to financial statements and exhibits, as well as other events and a Regulation FD disclosure. Specific financial figures or material events beyond the filing's nature are not detailed in the provided text.
Why It Matters
This 8-K filing indicates Karyopharm Therapeutics is providing updates to the SEC, which could include material information relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard corporate disclosure (8-K) and does not inherently contain negative news or significant risk factors on its own.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Registrant
- October 31, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- 001-36167 (identifier) — SEC File Number
- 26-3931704 (identifier) — IRS Employer Identification No.
- 85 Wells Avenue, 2nd Floor Newton, Massachusetts 02459 (address) — Principal Executive Offices
- (617) 658-0600 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Karyopharm Therapeutics Inc.?
The 8-K filing serves as a current report to the SEC, indicating the disclosure of material events, financial statements, and exhibits, as well as a Regulation FD disclosure.
On what date was this 8-K report filed?
The report was filed on October 31, 2024.
In which U.S. state is Karyopharm Therapeutics Inc. incorporated?
Karyopharm Therapeutics Inc. is incorporated in Delaware.
What is the principal executive office address for Karyopharm Therapeutics Inc.?
The principal executive offices are located at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459.
What is the SEC file number for Karyopharm Therapeutics Inc.?
The SEC file number for Karyopharm Therapeutics Inc. is 001-36167.
Filing Stats: 604 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-10-31 07:41:58
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
Filing Documents
- d891084d8k.htm (8-K) — 26KB
- d891084dex991.htm (EX-99.1) — 37KB
- g891084g1031060028500.jpg (GRAPHIC) — 3KB
- 0001193125-24-248162.txt ( ) — 198KB
- kpti-20241031.xsd (EX-101.SCH) — 3KB
- kpti-20241031_lab.xml (EX-101.LAB) — 18KB
- kpti-20241031_pre.xml (EX-101.PRE) — 11KB
- d891084d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 relating to Item 7.01 shall be deemed to be furnished, and not filed: 99.1 Press release issued by Karyopharm Therapeutics Inc. on October 31, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: October 31, 2024 By: /s/ Michael Mano Michael Mano Senior Vice President, General Counsel and Secretary